Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report
While multiple studies have demonstrated the efficacy and safety of efgartigimod, large-scale studies remain necessary to further evaluate the feasibility of combination therapy with rituximab in MuSK-Ab-positive MG.
Authors
- Houshi Zhou
- Tongtong Cai
- Xiujun Zheng
- Jing Wang
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shantou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1710017
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00